NETest in advanced high‐grade gastroenteropancreatic neuroendocrine neoplasms

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Clinical Value of a 51-Neuroendocrine Tumor–Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery2026
2. 2Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms2024 · 8 citations
3. 3Clinical Validity of NETest2.0® in Surveillance of Neuroendocrine Tumor Patients: Evidence from a NET Registry Study (NCT02270567)2026 · 2 citations
4. 4NETest2.0® Demonstrates Superior Monitoring Performance Compared with Chromogranin A in Neuroendocrine Tumor Surveillance2026
5. 5Clinicopathological Features and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Tumors: A Single-Center Experience2026 · 1 citations